The antiphospholipid syndrome (APS) is an autoimmune disorder characterized by vascular thrombosis and/or pregnancy morbidity (miscarriages, fetal deaths, premature births, etc.) associated with a persistent positivity for antiphospholipid antibodies (aPL). The current classification criteria for APS include three laboratory tests: lupus anticoagulant (LA), anticardiolipin (aCL), and anti-β 2 glycoprotein-I (β 2 GPI). To prevent detection of transient antibodies, tests must be positive on 2 occasions, at least 12 weeks apart.
1 β 2 GPI is hypothesized to be the main antigenic target for aPL, especially in vascular tissues after conformational modification.
2
Although some evidence is available supporting a role for anti-β 2 GPI antibodies in contributing to thrombosis and pregnancy morbidity, 3, 4 their pathogenicity remains a topic of heated discussion. In fact, not all patients positive for the presence of anti-β 2 GPI antibodies develop clinical aPL-related manifestations. 3 Besides, anti-β 2 GPI antibodies have also been detected in a large range of autoimmune diseases, such as multiple sclerosis, 5 and nonautoimmune diseases, such as leprosy and in children with atopic dermatitis, 6 with a vast heterogeneity in terms of titers and persistence. This heterogeneity in the pathogenic potential of anti-β 2 GPI antibodies might be ascribed to the molecular structure of β 2 GPI, presenting multiple antigenic specificities that can be targeted by different autoantibodies.
7 β 2 GPI has five homologous domains (DI-DV), and recently, several studies have focused on the epitope distribution of anti-β 2 GPI antibodies to identify their clinical role. [8] [9] [10] The main epitope to have been found to be associated with APS involves regions of DI, 9,11 and growing evidence has resulted in the identification of DI as the "immunodominant epitope." 10, 12, 13 Both in vitro and in vivo preliminary data are in line with this hypothesis, supporting a role for anti-β 2 GPI-DI antibodies in the development of APSrelated clinical manifestations.
14,15
However, the clinical role of such antibodies is still debated, and international criteria for derivation and confirmation of anti-β 2 GPI-DI antibodies are still lacking. 16 To date, the exact prevalence of anti-β 2 GPI-DI antibodies in patients with APS and the role of testing for anti-β 2 GPI-DI when assessing the thrombosis risk are unclear.
In this study, we aim to estimate the prevalence of anti-β 2 GPI-DI in patients with APS and to determine whether anti-β 2 GPI-DI-positive individuals are at greater risk of thrombosis when compared with individuals without anti-β 2 GPI-DI by systematically reviewing the literature.
Methods
A detailed literature search has been developed a priori to identify articles that reported findings from clinical and laboratory studies that tested anti-β 2 GPI-DI antibodies. Key words and subject terms included are as follows: ("beta 2-glycoprotein i" [ (2011) (2012) (2013) (2014) (2015) were screened and included in the analysis when meeting the inclusion criteria and not replicating studies published elsewhere.
Studies that met the criteria to evaluate the prevalence of anti-β 2 GPI-DI antibodies and their association with the thrombotic risk in patients with APS and control populations were systematically analyzed by two independent reviewers (M. R. and I. C.). Disagreements were resolved by consensus; if consensus could not be achieved, a third party (S. S.) would provide an assessment of eligibility. As the data on eligibility were dichotomous (eligible: yes/no), interrater agreement at both the title and abstract review stage and the full article review stage was determined by calculation of Cohen's kappa coefficient (k ¼ 0.93).
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Literature search strategy on the prevalence of positivity for anti-β 2 GPI-DI antibodies is shown in ►Fig. 1. We included in our analysis only studies reporting: (1) clinical data referring to aPL-related manifestations, (2) laboratory data including aCL, LA, and/or anti-β 2 GPI testing, and (3) anti-β 2 GPI-DI antibodies testing with detailed assay methodology, isotype analyzed, defined cutoffs of positivity for anti-β 2 GPI-DI antibodies. All published series including 10 or more patients meeting the aforementioned inclusion criteria were recorded. Methods of enrollment were also analyzed. Prevalence of anti-β 2 GPI-DI antibodies was compared between populations by Fisher's exact test, two-tailed, whereas results for association of positivity and risk of thrombosis were compared using odds ratios reported in the studies analyzed.
This study has been performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, 18 and the relative checklist can be supplied upon request.
Risk of Bias Assessment
Two reviewers (M. R. and S. S.) assessed the risk of bias of individual studies using the Newcastle-Ottawa Scale (NOS) for cohort studies, and the NOS for case-control studies. The NOS is a scoring tool used to assess quality of evidence and risk of bias for nonrandomized studies included in metaanalyses.
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Comment on Excluded Studies
A total of 13 studies, 20-32 including a total of 6,169 patients (comprising a total of 533 patients with APS and 68 with systemic lupus erythematosus [SLE]), which included testing of anti-β 2 GPI-DI antibodies in diverse cohorts of patients, were excluded from the analysis of prevalence. The exclusion of these studies was based on (1) the impossibility of extrapolating clinical or laboratory data, in particular when reporting the results of anti-β 2 GPI-DI positivity, 23, 26 (2) lack of reported data on anti-β 2 GPI-DI prevalence, 25 (3) no defined cutoffs of positivity, 27 and/or (4) testing results expressed only in relation to the control groups.
26
Data summarizing the studies excluded from the analysis are illustrated in ►Table 1. Prevalence of Antibodies Anti-β 2 GPI-DI in APS Patients Radin et al.
Statistical Analysis
A detailed statistical analysis has been developed a priori. Of 11 studies, 9 differentiated patients with APS between PAPS and SAPS, and only 5 out of 11 studies specified the results of anti-β 2 GPI-DI antibodies positivity stratifying for the presence of concomitant autoimmune diseases. Two studies out of 11 did not specify if the patients with APS were PAPS or SAPS.
Detection of anti-β 2 GPI-DI antibodies was performed with an enzyme-linked immunosorbent assay (ELISA) in 5 out of 11 studies, 9,37,41,42,44 whereas 6 out of 11 studies used a chemiluminescent immunoassay (CIA). 35, 36, [38] [39] [40] 43 All studies investigated the presence of immunoglobulin G (IgG) isotype, and one study 44 investigated the presence of IgM and IgA anti-β 2 GPI-DI also. The six studies that performed testing with CIA used the same cutoff of positivity (99th percentile: 20 chemiluminescence units [CU] ). Regarding the studies that used ELISA, three studies 9,37,41 expressed the cutoff of positivity as mean þ 3 standard deviation (SD) of the HC as reference, one study 44 used a cutoff at the 99th percentile of the HC, and lastly one study 42 used a cutoff at the 95th percentile of the HC. Data summarizing the main characteristics of the tests used to identify anti-β 2 GPI-DI antibodies are provided in ►Table 2.
None of the studies investigated persistent positivity to anti-β 2 GPI-DI antibodies.
Inclusion criteria for 6 out of 11 studies Results of the critical appraisal of the included studies according to NOS are shown in ►Table 3.
The overall estimated median prevalence of anti-β 2 GPI-DI antibodies in patients with APS and/or SLE was 44.3% (range: 26.7-55.4%). When focusing on patients with APS (either PAPS or SAPS), the estimated overall prevalence was high at 45.4%. Stratifying for diagnosis, a significantly higher prevalence of anti-β 2 GPI-DI antibodies was observed in patients with APS (either PAPS or SAPS) than those with SLE without previous history of thrombosis (45.4 vs. 26 .7%; p < 0.0001).
Data regarding the prevalence analysis are summarized in ►Table 4.
When stratifying patients for inclusion criteria used to enroll subjects in each study, a frequency of anti-β 2 GPI-DI positivity of 38.6% was found in those studies enrolling patients with APS according to the Sapporo criteria, 35 found no significant predictive correlation with thrombosis, but reported that patients with recurrent thrombosis showed higher titers of anti-β 2 GPI-DI antibodies. When pooling together the results of the 5 studies we calculated a significant association between anti-β 2 GPI-DI positivity and thrombotic events (mean OR 1.99; 95% CI 1.52-2.60;
The forest plot describing data on thrombotic risk association with anti-β 2 GPI-DI positivity is shown in ►Fig. 2.
Interestingly, three studies out of 5 reported a significant association between triple aPL positivity and anti-β 2 GPI-DI positivity.
35,36,42
Discussion
In this study, we report an overall median prevalence of anti-β 2 GPI-DI antibodies in APS/SLE patients of 44.3%. We observed a significant higher frequency of anti-β 2 GPI-DI in patients with APS (45.4%) when compared with SLE patients (26.7%). We noted an even higher prevalence of anti-β 2 GPI-DI positivity in patients with PAPS (55.4%), compared with that of patients with SAPS (43,2%). We should acknowledge that this observation might be biased by the small sample size of included patients with SAPS.
When separating data for inclusion criteria, we observed an overall significantly higher anti-β 2 GPI-DI positivity in the two studies that used as inclusion criteria the persistent positivity of anti-β 2 GPI antibodies. 9, 42 This observation is in line with the concept that being positive for anti-β 2 GPI antibodies seems to increase the likelihood of also being positive for anti-β 2 GPI-DI antibodies. However, Andreoli et al, in a cohort of 159 subjects with persistently positive, medium, or high-titer anti-β 2 GPI IgG, found that 105 (66%) were positive for anti-β 2 GPI-DI and 35 (22%) were positive for anti-DIV/V IgG. These observations might suggest that approximately a third of subjects positive for anti-β 2 GPI antibodies could be negative for anti-β 2 GPI-DI antibodies and positive for anti-β 2 GPI-D-IV-V antibodies.
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In our analysis, when pooling data together, we observed that anti-β 2 GPI-DI antibodies positivity doubled the risk for thrombotic events. In detail, four out of five studies found a significant association of anti-β 2 GPI-DI antibodies positivity with thrombotic events, whereas one study found no predictive correlation with thrombosis. However, one could speculate that these findings might be at least in part explained by the fact that anti-β 2 GPI-DI antibodies levels have been shown to be significantly higher in individuals with a triple-positive aPL profile, a well-identified category at increased risk for thromboembolic events.
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A common limitation of the studies that analyze noncriteria aPL is the small sample size. However, we found that 7 out of 11 studies eligible for prevalence analysis included a large cohort of patients (>100), supporting the strength of the observation. Similarly, our analysis included a total of 1,809 (range: 30-200) HC.
In the studies analyzed, two different laboratory tests were used to identify anti-β 2 GPI-DI antibodies (6 out of 11 studies used CLIA and 5 used ELISA). Some intrinsic differences due to the techniques might be speculated. However, recently, Willis and Pierangeli 23 reported a good qualitative (k ¼ 0.6) and quantitative (Spearman's rho ¼ 0.76) agreement between two laboratory tests: ELISA in house University College London and QUANTA Flash CIA (Inova Diagnostics). Nevertheless, despite the reported good agreement between the two test types, some additional considerations are worth mentioning. First, it is reasonable to suspect that the antigenic preparations (conformational peptide versus whole DI) could influence the test's ability to detected anti-β 2 GPI-DI antibodies. This difference might intrinsically influence the level of agreement between the studies considered in our analysis. Second, anti-β 2 GPI-DI testing might be influenced by the conformational changes of β 2 GPI that directly modify the exposure to the surface of DI. 45 In fact,
anti-β 2 GPI-DI antibodies have reactivity toward their target epitope only when DI is coated onto hydrophobic, but not hydrophilic plates. 32 Unfortunately, there is no study available that has specifically compared the concordance among techniques using different antigen preparations. Clinical manifestations of APS include vascular thrombosis and/or pregnancy morbidity. In our review, we analyzed the thrombotic risk assessment in relation to anti-β 2 GPI-DI antibodies positivity; however, no studies have reported a predictive association between pregnant morbidity and anti-β 2 GPI-DI positivity to our knowledge.
Recently, Müller-Calleja et al 21 investigated IgG anti-β 2 GPI-DI antibodies positivity with CIA in a large cohort of individuals (4,979 and 1,049 HC) to estimate the overall positivity in the general population. Although no significant difference was reported between the whole sample of individuals of the general population and the HCs, no detailed clinical data of the individuals included in the study was provided. Thus, although the general population is unlikely to benefit from indiscriminate screening for these antibodies, their detection in patients with SLE, connective tissue diseases, and/or previous thrombosis is justified by the high thrombotic risk associated with these clinical conditions.
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Strengths and Limitation of the Analysis
The strengths of this analysis lie on a priori designed search strategy, and the inclusion of gray literature searches and manual review of reference lists minimized the risk of missing eligible studies. We performed independent and duplicate review for study selection and data extraction. However, there are also limitations. All of the included studies were observational studies, subject to the biases inherent in such study designs.
Our research strategy did not include Scopus as per a priori designed protocol. Additionally, there was heterogeneity in the data in terms of inclusion criteria, assay heterogeneity, cutoff values definition, detected Ig isotypes, clinical details, control groups, and site of thrombosis. Moreover, none of the studies reported data comparing persistent versus transient anti-β 2 GPI-DI positivity. Also, only a minority of studies confirmed their findings by multivariate analysis. Furthermore, when analyzing the control groups used in the studies included in the analysis, no study included a control group consisted of event-free aPL carriers, limiting the generalizability of the role of anti-β 2 GPI-DI positivity in the different subgroups (e.g., thrombotic APS, obstetric APS, isolated aPL carries, aPL carriers in patients with SLE). Finally, while significant international improvements have been achieved in the standardization of IgG and IgM anti-β 2 GPI antibody measurement, 46,47 one could not exclude that some potential bias related to the availability of existing reference materials might still exist.
Conclusions
Despite the limitations of the studies included, we report an overall estimated median prevalence of 44.3% in patients with APS and/or SLE and a higher prevalence of anti-β 2 GPI-DI antibodies among patients with APS compared with SLE alone. Furthermore, when pooling data together, we observed that anti-β 2 GPI-DI antibodies positivity doubles the thrombotic risk compared with patients negative for anti-β 2 GPI-DI antibodies. Thus, anti-β 2 GPI-DI antibodies seem to be a potential candidate as a laboratory tool for the diagnosis of APS, in particular regarding thrombotic risk assessment. The inclusion of anti-β 2 GPI-DI antibodies as laboratory criteria for the APS should be indubitably explored.
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